Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01939730 · ClinicalTrials.gov registry record · Phase 2
Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT01939730: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01939730 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01939730, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to see if using the drugs Rituximab (IDEC-C2B8) and Granulocyte-macrophage colony-stimulating factor (GM-CSF) (Leukine) together is better than using rituximab alone to treat follicular B-cell lymphomas. The safety of this treatment will also be studied.
Interventions
- DRUG Rituximab
- DRUG GM-CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 1999-08 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01939730
The ClinicalTrials.gov registry entry for NCT01939730 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT01939730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01939730 about?
NCT01939730 is a clinical study titled "Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma". The goal of this clinical research study is to see if using the drugs Rituximab (IDEC-C2B8) and Granulocyte-macrophage colony-stimulating factor (GM-CSF) (Leukine) together is better than using rituximab alone to treat follicular B-cell lymphomas. The safety of this treatment will also be studied.
What is the current status of trial NCT01939730?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 1999-08. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01939730?
The interventions under investigation include: Rituximab (DRUG), GM-CSF (DRUG).
Who is sponsoring clinical trial NCT01939730?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.